Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.
Tesamorelin has a short detection window, with metabolites detectable in serum for up to 2 hours, suggesting that testing should focus on these metabolites rather than intact tesamorelin.
Where it sits
this study against the rest of the tesamorelin corpusSummary and findings
The study investigated the detection of tesamorelin and its metabolites in human urine and serum after administration. Six healthy volunteers received 10 consecutive days of tesamorelin injections. The study found that intact tesamorelin was detectable in serum for up to 30 minutes and metabolites for up to 2 hours post-injection.
Abstract
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue used for reducing excess abdominal fat in HIV-infected patients suffering from lipodystrophy. Together with other GHRH analogues, it is classified as a doping agent and is prohibited at all times according to the World Anti-Doping Agency (WADA). To investigate whether current testing methodologies are adequate for detecting tesamorelin abuse, an administration study was performed involving six healthy volunteers and 10 consecutive days of Egrifta (tesamorelin) injections, mimicking a doping protocol. A validated solid-phase extraction method was used to analyse the samples, reaching limits of detection of 13 pg/mL in urine and 41 pg/mL in serum. To account for the generation of metabolites by proteolytic degradation, tesamorelin was incubated in fresh human serum. Five previously unreported metabolites were found and identified, extending the detectability of tesamorelin abuse. Oxidation of the methionine residue was observed in tesamorelin and metabolites, hence ions to monitor the sulfoxide and sulfone forms were added to the methods. Despite a limit of detection 70 times lower than the WADA minimum required performance level and the inclusion of several metabolites, tesamorelin use could not be detected in post-administration urine. In serum, tesamorelin metabolites were detected in all six volunteers for up to 2 h after injection, whereas intact tesamorelin was detected in just two volunteers, up to 30 min post-administration. The outcome of this study shows that tesamorelin has a short detection window and testing methods should focus on metabolites in serum, rather than intact compounds in urine.
Background
This paper addresses the detection of tesamorelin, a GHRH analogue, in the context of doping regulations. Previous studies have indicated that GHRH analogues are prohibited by the World Anti-Doping Agency. Understanding the pharmacokinetics and detection methods for such substances is crucial for effective monitoring in sports.
Methods
The study involved six healthy volunteers who received daily injections of tesamorelin for 10 consecutive days. A validated solid-phase extraction method was employed to analyze urine and serum samples. The primary outcome was the detection of intact tesamorelin and its metabolites in these samples.
Results
Intact tesamorelin was detected in serum for up to 30 min post-administration in two volunteers. In urine, tesamorelin use could not be detected post-administration. Metabolites were detected in serum for up to 2 h after injection in all six volunteers.
Interpretation
The findings suggest that while tesamorelin and its metabolites can be detected in serum, the short detection window limits the effectiveness of current testing methods. This aligns with prior literature indicating challenges in detecting GHRH analogues. The small sample size and focus on detection rather than broader implications limit the conclusions that can be drawn.
Key findings
- Limits of detection were 13 pg/mL in urine and 41 pg/mL in serum.
- Intact tesamorelin was detected in serum for up to 30 min post-administration in two volunteers.
- Tesamorelin metabolites were detected in all six volunteers for up to 2 h after injection.
- Tesamorelin use could not be detected in post-administration urine.
- Five previously unreported metabolites were identified.
Limitations
- small sample size of six volunteers
- study focused solely on detection capabilities
- short follow-up period post-administration
- not applicable for broader implications of tesamorelin use